Levodopa/DDCI and entacapone is the preferred treatment for Parkinson’s disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort
Identifieur interne : 000C74 ( Istex/Corpus ); précédent : 000C73; suivant : 000C75Levodopa/DDCI and entacapone is the preferred treatment for Parkinson’s disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort
Auteurs : P. Damier ; F. Viallet ; M. Ziegler ; I. Bourdeix ; K. ReratSource :
- European Journal of Neurology [ 1351-5101 ] ; 2008-07.
English descriptors
Abstract
Levodopa is the gold standard drug for the symptomatic control of Parkinson’s disease (PD). However, long‐term treatment with conventional formulations [levodopa and a dopa decarboxylase inhibitor (DDCI)], is associated with re‐emergence of symptoms because of wearing‐off and dyskinesia. Treatment with levodopa/DDCI and entacapone extends the half‐life of levodopa, avoiding deep troughs in levodopa plasma levels and providing more continuous delivery of levodopa to the brain. In this open‐label, retrospective, observational study we investigated the effects of levodopa/DDCI and entacapone therapy in 800 PD patients with motor fluctuations. Levodopa/DDCI and entacapone treatment was assessed as good/very good in improving motor fluctuations (64%) and activities of daily living (ADL; 62%). The therapeutic utility was considered to be good/very good in 70% of cases. Moreover, there was a reduction in levodopa dose in 20% of patients. Neurologists preferred levodopa/DDCI and entacapone compared with increasing levodopa dosage, dose‐fractionation or addition of a dopamine agonist (63%, 29% and 23% of patients respectively). Reasons included achieving more continuous dopaminergic stimulation (40%), reducing motor fluctuations (54%) and improving ADL (41%). This analysis reveals the preference of neurologists for levodopa/DDCI and entacapone over conventional levodopa‐modification strategies for the effective treatment of PD motor fluctuations in clinical practice.
Url:
DOI: 10.1111/j.1468-1331.2008.02165.x
Links to Exploration step
ISTEX:FB1AF7A778E8460826C64B435617CFBBC987FCD1Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Levodopa/DDCI and entacapone is the preferred treatment for Parkinson’s disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort</title><author><name sortKey="Damier, P" sort="Damier, P" uniqKey="Damier P" first="P." last="Damier">P. Damier</name><affiliation><mods:affiliation>INSERM, CIC04, Nantes, France and CHU Nantes, Clinique Neurologique, Nantes, France</mods:affiliation></affiliation></author><author><name sortKey="Viallet, F" sort="Viallet, F" uniqKey="Viallet F" first="F." last="Viallet">F. Viallet</name><affiliation><mods:affiliation>Service de Neurologie, CH du Pays d’Aix, Aix en Provence, France</mods:affiliation></affiliation></author><author><name sortKey="Ziegler, M" sort="Ziegler, M" uniqKey="Ziegler M" first="M." last="Ziegler">M. Ziegler</name><affiliation><mods:affiliation>Hopital Léopold Belan, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Bourdeix, I" sort="Bourdeix, I" uniqKey="Bourdeix I" first="I." last="Bourdeix">I. Bourdeix</name><affiliation><mods:affiliation>Novartis Pharma S.A.S, Rueil‐Malmaison Cedex, France</mods:affiliation></affiliation></author><author><name sortKey="Rerat, K" sort="Rerat, K" uniqKey="Rerat K" first="K." last="Rerat">K. Rerat</name><affiliation><mods:affiliation>Novartis Pharma S.A.S, Rueil‐Malmaison Cedex, France</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:FB1AF7A778E8460826C64B435617CFBBC987FCD1</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1111/j.1468-1331.2008.02165.x</idno><idno type="url">https://api.istex.fr/document/FB1AF7A778E8460826C64B435617CFBBC987FCD1/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000C74</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000C74</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Levodopa/DDCI and entacapone is the preferred treatment for Parkinson’s disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort</title><author><name sortKey="Damier, P" sort="Damier, P" uniqKey="Damier P" first="P." last="Damier">P. Damier</name><affiliation><mods:affiliation>INSERM, CIC04, Nantes, France and CHU Nantes, Clinique Neurologique, Nantes, France</mods:affiliation></affiliation></author><author><name sortKey="Viallet, F" sort="Viallet, F" uniqKey="Viallet F" first="F." last="Viallet">F. Viallet</name><affiliation><mods:affiliation>Service de Neurologie, CH du Pays d’Aix, Aix en Provence, France</mods:affiliation></affiliation></author><author><name sortKey="Ziegler, M" sort="Ziegler, M" uniqKey="Ziegler M" first="M." last="Ziegler">M. Ziegler</name><affiliation><mods:affiliation>Hopital Léopold Belan, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Bourdeix, I" sort="Bourdeix, I" uniqKey="Bourdeix I" first="I." last="Bourdeix">I. Bourdeix</name><affiliation><mods:affiliation>Novartis Pharma S.A.S, Rueil‐Malmaison Cedex, France</mods:affiliation></affiliation></author><author><name sortKey="Rerat, K" sort="Rerat, K" uniqKey="Rerat K" first="K." last="Rerat">K. Rerat</name><affiliation><mods:affiliation>Novartis Pharma S.A.S, Rueil‐Malmaison Cedex, France</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">European Journal of Neurology</title><idno type="ISSN">1351-5101</idno><idno type="eISSN">1468-1331</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2008-07">2008-07</date><biblScope unit="volume">15</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="643">643</biblScope><biblScope unit="page" to="648">648</biblScope></imprint><idno type="ISSN">1351-5101</idno></series><idno type="istex">FB1AF7A778E8460826C64B435617CFBBC987FCD1</idno><idno type="DOI">10.1111/j.1468-1331.2008.02165.x</idno><idno type="ArticleID">ENE2165</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1351-5101</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>activities of daily living</term><term>entacapone</term><term>levodopa</term><term>motor fluctuations</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Levodopa is the gold standard drug for the symptomatic control of Parkinson’s disease (PD). However, long‐term treatment with conventional formulations [levodopa and a dopa decarboxylase inhibitor (DDCI)], is associated with re‐emergence of symptoms because of wearing‐off and dyskinesia. Treatment with levodopa/DDCI and entacapone extends the half‐life of levodopa, avoiding deep troughs in levodopa plasma levels and providing more continuous delivery of levodopa to the brain. In this open‐label, retrospective, observational study we investigated the effects of levodopa/DDCI and entacapone therapy in 800 PD patients with motor fluctuations. Levodopa/DDCI and entacapone treatment was assessed as good/very good in improving motor fluctuations (64%) and activities of daily living (ADL; 62%). The therapeutic utility was considered to be good/very good in 70% of cases. Moreover, there was a reduction in levodopa dose in 20% of patients. Neurologists preferred levodopa/DDCI and entacapone compared with increasing levodopa dosage, dose‐fractionation or addition of a dopamine agonist (63%, 29% and 23% of patients respectively). Reasons included achieving more continuous dopaminergic stimulation (40%), reducing motor fluctuations (54%) and improving ADL (41%). This analysis reveals the preference of neurologists for levodopa/DDCI and entacapone over conventional levodopa‐modification strategies for the effective treatment of PD motor fluctuations in clinical practice.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>P. Damier</name><affiliations><json:string>INSERM, CIC04, Nantes, France and CHU Nantes, Clinique Neurologique, Nantes, France</json:string></affiliations></json:item><json:item><name>F. Viallet</name><affiliations><json:string>Service de Neurologie, CH du Pays d’Aix, Aix en Provence, France</json:string></affiliations></json:item><json:item><name>M. Ziegler</name><affiliations><json:string>Hopital Léopold Belan, Paris, France</json:string></affiliations></json:item><json:item><name>I. Bourdeix</name><affiliations><json:string>Novartis Pharma S.A.S, Rueil‐Malmaison Cedex, France</json:string></affiliations></json:item><json:item><name>K. Rerat</name><affiliations><json:string>Novartis Pharma S.A.S, Rueil‐Malmaison Cedex, France</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>activities of daily living</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>entacapone</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>levodopa</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>motor fluctuations</value></json:item></subject><articleId><json:string>ENE2165</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>reviewArticle</json:string></originalGenre><abstract>Levodopa is the gold standard drug for the symptomatic control of Parkinson’s disease (PD). However, long‐term treatment with conventional formulations [levodopa and a dopa decarboxylase inhibitor (DDCI)], is associated with re‐emergence of symptoms because of wearing‐off and dyskinesia. Treatment with levodopa/DDCI and entacapone extends the half‐life of levodopa, avoiding deep troughs in levodopa plasma levels and providing more continuous delivery of levodopa to the brain. In this open‐label, retrospective, observational study we investigated the effects of levodopa/DDCI and entacapone therapy in 800 PD patients with motor fluctuations. Levodopa/DDCI and entacapone treatment was assessed as good/very good in improving motor fluctuations (64%) and activities of daily living (ADL; 62%). The therapeutic utility was considered to be good/very good in 70% of cases. Moreover, there was a reduction in levodopa dose in 20% of patients. Neurologists preferred levodopa/DDCI and entacapone compared with increasing levodopa dosage, dose‐fractionation or addition of a dopamine agonist (63%, 29% and 23% of patients respectively). Reasons included achieving more continuous dopaminergic stimulation (40%), reducing motor fluctuations (54%) and improving ADL (41%). This analysis reveals the preference of neurologists for levodopa/DDCI and entacapone over conventional levodopa‐modification strategies for the effective treatment of PD motor fluctuations in clinical practice.</abstract><qualityIndicators><score>5.608</score><pdfVersion>1.3</pdfVersion><pdfPageSize>595.276 x 782.362 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1482</abstractCharCount><pdfWordCount>3220</pdfWordCount><pdfCharCount>22298</pdfCharCount><pdfPageCount>6</pdfPageCount><abstractWordCount>199</abstractWordCount></qualityIndicators><title>Levodopa/DDCI and entacapone is the preferred treatment for Parkinson’s disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort</title><refBibs><json:item><author><json:item><name>Y Agid</name></json:item><json:item><name>CW Olanow</name></json:item><json:item><name>Y Mizuno</name></json:item></author><host><volume>360</volume><pages><first>575</first></pages><author></author><title>Lancet</title></host><title>Levodopa: why the controversy?</title></json:item><json:item><author><json:item><name>JA Obeso</name></json:item><json:item><name>MC Rodriguez‐Oroz</name></json:item><json:item><name>P Chana</name></json:item><json:item><name>G Lera</name></json:item><json:item><name>M Rodriguez</name></json:item><json:item><name>CW Olanow</name></json:item></author><host><volume>55</volume><pages><last>20</last><first>13</first></pages><author></author><title>Neurology</title></host><title>The evolution and origin of motor complications in Parkinson’s disease</title></json:item><json:item><author><json:item><name>JE Ahlskog</name></json:item><json:item><name>MD Muenter</name></json:item></author><host><volume>16</volume><pages><last>458</last><first>448</first></pages><author></author><title>Movement Disorders</title></host><title>Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature</title></json:item><json:item><author><json:item><name>CH Adler</name></json:item></author><host><volume>58</volume><pages><last>56</last><first>51</first></pages><author></author><title>Neurology</title></host><title>Relevance of motor complications in Parkinson’s disease</title></json:item><json:item><author><json:item><name>F Stocchi</name></json:item><json:item><name>L Vacca</name></json:item><json:item><name>S Ruggieri</name></json:item><json:item><name>CW Olanow</name></json:item></author><host><volume>62</volume><pages><last>910</last><first>905</first></pages><author></author><title>Archives of Neurology</title></host><title>Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study</title></json:item><json:item><author><json:item><name>CW Olanow</name></json:item><json:item><name>JA Obeso</name></json:item><json:item><name>F Stocchi</name></json:item></author><host><volume>5</volume><pages><last>687</last><first>677</first></pages><author></author><title>Lancet Neurology</title></host><title>Continuous dopamine‐receptor treatment of Parkinson’s disease: scientific rationale and clinical implications</title></json:item><json:item><author><json:item><name>R De La Fuente‐Fernandez</name></json:item><json:item><name>JQ Lu</name></json:item><json:item><name>V Sossi</name></json:item></author><host><volume>49</volume><pages><last>303</last><first>298</first></pages><author></author><title>Annals of Neurology</title></host><title>Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson’s disease: PET evidence of increased dopamine turnover</title></json:item><json:item><author><json:item><name>W Olanow</name></json:item><json:item><name>AH Schapira</name></json:item><json:item><name>O Rascol</name></json:item></author><host><volume>23</volume><pages><last>126</last><first>117</first></pages><author></author><title>Trends in Neuroscience</title></host><title>Continuous dopamine‐receptor stimulation in early Parkinson’s disease</title></json:item><json:item><author><json:item><name>F Stocchi</name></json:item></author><host><volume>7</volume><pages><last>1407</last><first>1399</first></pages><author></author><title>Expert Opinion on Pharmacotherapy</title></host><title>The levodopa wearing‐off phenomenon in Parkinson’s disease: pharmacokinetic considerations</title></json:item><json:item><author><json:item><name>HM Ruottinen</name></json:item><json:item><name>UK Rinne</name></json:item></author><host><volume>19</volume><pages><last>296</last><first>283</first></pages><author></author><title>Clinical Neuropharmacology</title></host><title>A double‐blind pharmacokinetic and clinical dose‐response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson’s disease</title></json:item><json:item><author><json:item><name> </name></json:item></author><host><volume>42</volume><pages><last>755</last><first>747</first></pages><author></author><title>Annals of Neurology</title></host><title>Entacapone improves motor fluctuations in levodopa‐treated Parkinson’s disease patients. Parkinson Study Group</title></json:item><json:item><author><json:item><name>UK Rinne</name></json:item><json:item><name>JP Larsen</name></json:item><json:item><name>A Siden</name></json:item><json:item><name>J Worm‐Petersen</name></json:item></author><host><volume>51</volume><pages><last>1314</last><first>1309</first></pages><author></author><title>Neurology</title></host><title>Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group</title></json:item><json:item><author><json:item><name>WH Poewe</name></json:item><json:item><name>G Deuschl</name></json:item><json:item><name>A Gordin</name></json:item><json:item><name>ER Kultalahti</name></json:item><json:item><name>M Leinonen</name></json:item></author><host><volume>105</volume><pages><last>255</last><first>245</first></pages><author></author><title>Acta Neurologica Scandinavica</title></host><title>Efficacy and safety of entacapone in Parkinson’s disease patients with suboptimal levodopa response: a 6‐month randomized placebo‐controlled double‐blind study in Germany and Austria (Celomen study)</title></json:item><json:item><author><json:item><name>DJ Brooks</name></json:item><json:item><name>H Sagar</name></json:item></author><host><volume>74</volume><pages><last>1079</last><first>1071</first></pages><author></author><title>Journal of Neurology, Neurosurgery and Psychiatry</title></host><title>Entacapone is beneficial in both fluctuating and non‐fluctuating patients with Parkinson’s disease: a randomised, placebo controlled, double blind, six month study</title></json:item><json:item><author><json:item><name>JP Larsen</name></json:item><json:item><name>J Worm‐Petersen</name></json:item><json:item><name>A Siden</name></json:item><json:item><name>A Gordin</name></json:item><json:item><name>K Reinikainen</name></json:item><json:item><name>M Leinonen</name></json:item></author><host><volume>10</volume><pages><last>146</last><first>137</first></pages><author></author><title>European Journal of Neurology</title></host><title>The tolerability and efficacy of entacapone over 3 years in patients with Parkinson’s disease</title></json:item><json:item><author><json:item><name>G Fenelon</name></json:item><json:item><name>S Gimenez‐Roldan</name></json:item><json:item><name>JL Montastruc</name></json:item></author><host><volume>110</volume><pages><last>251</last><first>239</first></pages><author></author><title>Journal of NeuralTransmission</title></host><title>Efficacy and tolerability of entacapone in patients with Parkinson’s disease treated with levodopa plus a dopamine agonist and experiencing wearing‐off motor fluctuations. A randomized, double‐blind, multicentre study</title></json:item><json:item><author><json:item><name>F Durif</name></json:item><json:item><name>I Devaux</name></json:item><json:item><name>JJ Pere</name></json:item><json:item><name>JC Delumeau</name></json:item><json:item><name>I Bourdeix</name></json:item></author><host><volume>45</volume><pages><last>118</last><first>111</first></pages><author></author><title>European Neurology</title></host><title>Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson’s disease and end‐of‐dose deterioration in daily medical practice: an open, multicenter study</title></json:item><json:item><author><json:item><name>AJ Hughes</name></json:item><json:item><name>SE Daniel</name></json:item><json:item><name>L Kilford</name></json:item><json:item><name>AJ Lees</name></json:item></author><host><volume>55</volume><pages><last>184</last><first>181</first></pages><author></author><title>Journal of Neurology, Neurosurgery and Psychiatry</title></host><title>Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico‐pathological study of 100 cases</title></json:item><json:item><author><json:item><name>A Kupsch</name></json:item><json:item><name>T Trottenberg</name></json:item><json:item><name>D Bremen</name></json:item></author><host><volume>20</volume><pages><last>120</last><first>115</first></pages><author></author><title>Current Medical Research and Opinion</title></host><title>Levodopa therapy with entacapone in daily clinical practice: results of a post‐marketing surveillance study</title></json:item><json:item><author><json:item><name>S Fahn</name></json:item><json:item><name>D Oakes</name></json:item><json:item><name>I Shoulson</name></json:item></author><host><volume>351</volume><pages><last>2508</last><first>2498</first></pages><author></author><title>New England Journal of Medicine</title></host><title>Levodopa and the progression of Parkinson’s disease</title></json:item><json:item><author><json:item><name>RG Fariello</name></json:item></author><host><volume>55</volume><pages><last>16</last><first>10</first></pages><issue>Suppl. 1</issue><author></author><title>Drugs</title></host><title>Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson’s disease</title></json:item><json:item><author><json:item><name>CW Olanow</name></json:item><json:item><name>RL Watts</name></json:item><json:item><name>WC Koller</name></json:item></author><host><volume>56</volume><pages><last>88</last><first>1</first></pages><author></author><title>Neurology</title></host><title>An algorithm (decision tree) for the management of Parkinson’s disease (2001): treatment guidelines</title></json:item><json:item><author><json:item><name> </name></json:item></author><host><volume>17</volume><pages><last>166</last><first>1</first></pages><author></author><title>Movement Disorders</title></host><title>Management of Parkinson’s disease: an evidence‐based review</title></json:item><json:item><author><json:item><name>A Gordin</name></json:item><json:item><name>S Kaakkola</name></json:item><json:item><name>K Teravainen</name></json:item></author><host><pages><last>250</last><first>237</first></pages><author></author><title>Parkinson’s Disease: Advances in Neurology</title></host><title>Position of COMT inhibition in the treatment of Parkinson’s disease</title></json:item><json:item><author><json:item><name>T Muller</name></json:item><json:item><name>C Erdmann</name></json:item><json:item><name>S Muhlack</name></json:item></author><host><volume>113</volume><pages><last>1448</last><first>1441</first></pages><author></author><title>Journal of Neural Transmission</title></host><title>Pharmacokinetic behaviour of levodopa and 3‐O‐methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson’s disease</title></json:item><json:item><author><json:item><name>F Stocchi</name></json:item><json:item><name>CW Olanow</name></json:item></author><host><volume>62</volume><pages><last>63</last><first>56</first></pages><author></author><title>Neurology</title></host><title>Continuous dopaminergic stimulation in early and advanced Parkinson’s disease</title></json:item></refBibs><genre><json:string>review-article</json:string></genre><host><volume>15</volume><publisherId><json:string>ENE</json:string></publisherId><pages><total>6</total><last>648</last><first>643</first></pages><issn><json:string>1351-5101</json:string></issn><issue>7</issue><genre><json:string>journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1468-1331</json:string></eissn><title>European Journal of Neurology</title><doi><json:string>10.1111/(ISSN)1468-1331</json:string></doi></host><categories><wos><json:string>science</json:string><json:string>neurosciences</json:string><json:string>clinical neurology</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>clinical medicine</json:string><json:string>neurology & neurosurgery</json:string></scienceMetrix></categories><publicationDate>2008</publicationDate><copyrightDate>2008</copyrightDate><doi><json:string>10.1111/j.1468-1331.2008.02165.x</json:string></doi><id>FB1AF7A778E8460826C64B435617CFBBC987FCD1</id><score>0.2523102</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/FB1AF7A778E8460826C64B435617CFBBC987FCD1/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/FB1AF7A778E8460826C64B435617CFBBC987FCD1/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/FB1AF7A778E8460826C64B435617CFBBC987FCD1/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Levodopa/DDCI and entacapone is the preferred treatment for Parkinson’s disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><availability><p>© 2008 The Author(s). Journal compilation © 2008 EFNS</p></availability><date>2008</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Levodopa/DDCI and entacapone is the preferred treatment for Parkinson’s disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort</title><author xml:id="author-1"><persName><forename type="first">P.</forename><surname>Damier</surname></persName><affiliation>INSERM, CIC04, Nantes, France and CHU Nantes, Clinique Neurologique, Nantes, France</affiliation></author><author xml:id="author-2"><persName><forename type="first">F.</forename><surname>Viallet</surname></persName><affiliation>Service de Neurologie, CH du Pays d’Aix, Aix en Provence, France</affiliation></author><author xml:id="author-3"><persName><forename type="first">M.</forename><surname>Ziegler</surname></persName><affiliation>Hopital Léopold Belan, Paris, France</affiliation></author><author xml:id="author-4"><persName><forename type="first">I.</forename><surname>Bourdeix</surname></persName><affiliation>Novartis Pharma S.A.S, Rueil‐Malmaison Cedex, France</affiliation></author><author xml:id="author-5"><persName><forename type="first">K.</forename><surname>Rerat</surname></persName><affiliation>Novartis Pharma S.A.S, Rueil‐Malmaison Cedex, France</affiliation></author></analytic><monogr><title level="j">European Journal of Neurology</title><idno type="pISSN">1351-5101</idno><idno type="eISSN">1468-1331</idno><idno type="DOI">10.1111/(ISSN)1468-1331</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2008-07"></date><biblScope unit="volume">15</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="643">643</biblScope><biblScope unit="page" to="648">648</biblScope></imprint></monogr><idno type="istex">FB1AF7A778E8460826C64B435617CFBBC987FCD1</idno><idno type="DOI">10.1111/j.1468-1331.2008.02165.x</idno><idno type="ArticleID">ENE2165</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2008</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Levodopa is the gold standard drug for the symptomatic control of Parkinson’s disease (PD). However, long‐term treatment with conventional formulations [levodopa and a dopa decarboxylase inhibitor (DDCI)], is associated with re‐emergence of symptoms because of wearing‐off and dyskinesia. Treatment with levodopa/DDCI and entacapone extends the half‐life of levodopa, avoiding deep troughs in levodopa plasma levels and providing more continuous delivery of levodopa to the brain. In this open‐label, retrospective, observational study we investigated the effects of levodopa/DDCI and entacapone therapy in 800 PD patients with motor fluctuations. Levodopa/DDCI and entacapone treatment was assessed as good/very good in improving motor fluctuations (64%) and activities of daily living (ADL; 62%). The therapeutic utility was considered to be good/very good in 70% of cases. Moreover, there was a reduction in levodopa dose in 20% of patients. Neurologists preferred levodopa/DDCI and entacapone compared with increasing levodopa dosage, dose‐fractionation or addition of a dopamine agonist (63%, 29% and 23% of patients respectively). Reasons included achieving more continuous dopaminergic stimulation (40%), reducing motor fluctuations (54%) and improving ADL (41%). This analysis reveals the preference of neurologists for levodopa/DDCI and entacapone over conventional levodopa‐modification strategies for the effective treatment of PD motor fluctuations in clinical practice.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>keywords</head><item><term>activities of daily living</term></item><item><term>entacapone</term></item><item><term>levodopa</term></item><item><term>motor fluctuations</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2008-07">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/FB1AF7A778E8460826C64B435617CFBBC987FCD1/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Publishing Ltd</publisherName><publisherLoc>Oxford, UK</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1468-1331</doi><issn type="print">1351-5101</issn><issn type="electronic">1468-1331</issn><idGroup><id type="product" value="ENE"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="EUROPEAN JOURNAL OF NEUROLOGY">European Journal of Neurology</title></titleGroup></publicationMeta><publicationMeta level="part" position="07007"><doi origin="wiley">10.1111/ene.2008.15.issue-7</doi><numberingGroup><numbering type="journalVolume" number="15">15</numbering><numbering type="journalIssue" number="7">7</numbering></numberingGroup><coverDate startDate="2008-07">July 2008</coverDate></publicationMeta><publicationMeta level="unit" type="reviewArticle" position="3" status="forIssue"><doi origin="wiley">10.1111/j.1468-1331.2008.02165.x</doi><idGroup><id type="unit" value="ENE2165"></id></idGroup><countGroup><count type="pageTotal" number="6"></count></countGroup><titleGroup><title type="tocHeading1">Review Article</title></titleGroup><copyright>© 2008 The Author(s). Journal compilation © 2008 EFNS</copyright><eventGroup><event type="firstOnline" date="2008-06-10"></event><event type="publishedOnlineFinalForm" date="2008-06-10"></event><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-06"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-24"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-16"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="643">643</numbering><numbering type="pageLast" number="648">648</numbering></numberingGroup><correspondenceTo>Prof. Philippe Damier, Clinique Neurologique – Centre d’Investigation Clinique – INSERM U643, Hôpital Laěnnec, CHU Nantes, 44093 Nantes, France (tel.: +33 (0)2 40 16 52 05; fax: +33 (0)2 40 16 52 03; e‐mail: <email normalForm="philippe.damier@chu-nantes.fr">philippe.damier@chu‐nantes.fr</email>).</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:ENE.ENE2165.pdf"></link></linkGroup></publicationMeta><contentMeta><unparsedEditorialHistory>Received 20 August 2007 Accepted 31 March 2008</unparsedEditorialHistory><countGroup><count type="figureTotal" number="2"></count><count type="tableTotal" number="1"></count></countGroup><titleGroup><title type="main">Levodopa/DDCI and entacapone is the preferred treatment for Parkinson’s disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort</title><title type="shortAuthors">P. Damier <i>et al.</i></title><title type="short">Levodopa/DDCI and entacapone is preferred for treatment of motor fluctuations in clinical practice</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a1"><personName><givenNames>P.</givenNames><familyName>Damier</familyName></personName></creator><creator creatorRole="author" xml:id="cr2" affiliationRef="#a2"><personName><givenNames>F.</givenNames><familyName>Viallet</familyName></personName></creator><creator creatorRole="author" xml:id="cr3" affiliationRef="#a3"><personName><givenNames>M.</givenNames><familyName>Ziegler</familyName></personName></creator><creator creatorRole="author" xml:id="cr4" affiliationRef="#a4"><personName><givenNames>I.</givenNames><familyName>Bourdeix</familyName></personName></creator><creator creatorRole="author" xml:id="cr5" affiliationRef="#a4"><personName><givenNames>K.</givenNames><familyName>Rerat</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="a1" countryCode="FR"><unparsedAffiliation>INSERM, CIC04, Nantes, France and CHU Nantes, Clinique Neurologique, Nantes, France</unparsedAffiliation></affiliation><affiliation xml:id="a2" countryCode="FR"><unparsedAffiliation>Service de Neurologie, CH du Pays d’Aix, Aix en Provence, France</unparsedAffiliation></affiliation><affiliation xml:id="a3" countryCode="FR"><unparsedAffiliation>Hopital Léopold Belan, Paris, France</unparsedAffiliation></affiliation><affiliation xml:id="a4" countryCode="FR"><unparsedAffiliation>Novartis Pharma S.A.S, Rueil‐Malmaison Cedex, France</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en"><keyword xml:id="k1">activities of daily living</keyword><keyword xml:id="k2">entacapone</keyword><keyword xml:id="k3">levodopa</keyword><keyword xml:id="k4">motor fluctuations</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><p>Levodopa is the gold standard drug for the symptomatic control of Parkinson’s disease (PD). However, long‐term treatment with conventional formulations [levodopa and a dopa decarboxylase inhibitor (DDCI)], is associated with re‐emergence of symptoms because of wearing‐off and dyskinesia. Treatment with levodopa/DDCI and entacapone extends the half‐life of levodopa, avoiding deep troughs in levodopa plasma levels and providing more continuous delivery of levodopa to the brain. In this open‐label, retrospective, observational study we investigated the effects of levodopa/DDCI and entacapone therapy in 800 PD patients with motor fluctuations. Levodopa/DDCI and entacapone treatment was assessed as good/very good in improving motor fluctuations (64%) and activities of daily living (ADL; 62%). The therapeutic utility was considered to be good/very good in 70% of cases. Moreover, there was a reduction in levodopa dose in 20% of patients. Neurologists preferred levodopa/DDCI and entacapone compared with increasing levodopa dosage, dose‐fractionation or addition of a dopamine agonist (63%, 29% and 23% of patients respectively). Reasons included achieving more continuous dopaminergic stimulation (40%), reducing motor fluctuations (54%) and improving ADL (41%). This analysis reveals the preference of neurologists for levodopa/DDCI and entacapone over conventional levodopa‐modification strategies for the effective treatment of PD motor fluctuations in clinical practice.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Levodopa/DDCI and entacapone is the preferred treatment for Parkinson’s disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Levodopa/DDCI and entacapone is preferred for treatment of motor fluctuations in clinical practice</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Levodopa/DDCI and entacapone is the preferred treatment for Parkinson’s disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort</title></titleInfo><name type="personal"><namePart type="given">P.</namePart><namePart type="family">Damier</namePart><affiliation>INSERM, CIC04, Nantes, France and CHU Nantes, Clinique Neurologique, Nantes, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">F.</namePart><namePart type="family">Viallet</namePart><affiliation>Service de Neurologie, CH du Pays d’Aix, Aix en Provence, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Ziegler</namePart><affiliation>Hopital Léopold Belan, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">I.</namePart><namePart type="family">Bourdeix</namePart><affiliation>Novartis Pharma S.A.S, Rueil‐Malmaison Cedex, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K.</namePart><namePart type="family">Rerat</namePart><affiliation>Novartis Pharma S.A.S, Rueil‐Malmaison Cedex, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="review-article" displayLabel="reviewArticle"></genre><originInfo><publisher>Blackwell Publishing Ltd</publisher><place><placeTerm type="text">Oxford, UK</placeTerm></place><dateIssued encoding="w3cdtf">2008-07</dateIssued><edition>Received 20 August 2007 Accepted 31 March 2008</edition><copyrightDate encoding="w3cdtf">2008</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">2</extent><extent unit="tables">1</extent></physicalDescription><abstract lang="en">Levodopa is the gold standard drug for the symptomatic control of Parkinson’s disease (PD). However, long‐term treatment with conventional formulations [levodopa and a dopa decarboxylase inhibitor (DDCI)], is associated with re‐emergence of symptoms because of wearing‐off and dyskinesia. Treatment with levodopa/DDCI and entacapone extends the half‐life of levodopa, avoiding deep troughs in levodopa plasma levels and providing more continuous delivery of levodopa to the brain. In this open‐label, retrospective, observational study we investigated the effects of levodopa/DDCI and entacapone therapy in 800 PD patients with motor fluctuations. Levodopa/DDCI and entacapone treatment was assessed as good/very good in improving motor fluctuations (64%) and activities of daily living (ADL; 62%). The therapeutic utility was considered to be good/very good in 70% of cases. Moreover, there was a reduction in levodopa dose in 20% of patients. Neurologists preferred levodopa/DDCI and entacapone compared with increasing levodopa dosage, dose‐fractionation or addition of a dopamine agonist (63%, 29% and 23% of patients respectively). Reasons included achieving more continuous dopaminergic stimulation (40%), reducing motor fluctuations (54%) and improving ADL (41%). This analysis reveals the preference of neurologists for levodopa/DDCI and entacapone over conventional levodopa‐modification strategies for the effective treatment of PD motor fluctuations in clinical practice.</abstract><subject lang="en"><genre>keywords</genre><topic>activities of daily living</topic><topic>entacapone</topic><topic>levodopa</topic><topic>motor fluctuations</topic></subject><relatedItem type="host"><titleInfo><title>European Journal of Neurology</title></titleInfo><genre type="journal">journal</genre><identifier type="ISSN">1351-5101</identifier><identifier type="eISSN">1468-1331</identifier><identifier type="DOI">10.1111/(ISSN)1468-1331</identifier><identifier type="PublisherID">ENE</identifier><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><detail type="issue"><caption>no.</caption><number>7</number></detail><extent unit="pages"><start>643</start><end>648</end><total>6</total></extent></part></relatedItem><identifier type="istex">FB1AF7A778E8460826C64B435617CFBBC987FCD1</identifier><identifier type="DOI">10.1111/j.1468-1331.2008.02165.x</identifier><identifier type="ArticleID">ENE2165</identifier><accessCondition type="use and reproduction" contentType="copyright">© 2008 The Author(s). Journal compilation © 2008 EFNS</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Blackwell Publishing Ltd</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C74 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000C74 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:FB1AF7A778E8460826C64B435617CFBBC987FCD1
|texte= Levodopa/DDCI and entacapone is the preferred treatment for Parkinson’s disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort
}}
| This area was generated with Dilib version V0.6.29. |  |